Limit Confusion and Other Issues With Paxlovid

July 2022

You can help prevent problems when patients taking nirmatrelvir/ritonavir (Paxlovid) for COVID-19 are admitted.

High-risk OUTpatients with a positive COVID-19 test should start this antiviral combo within 5 days of symptom onset.

And if a patient is hospitalized before the course is complete, clinicians may want to finish it.

Practical advice for a better career, with unlimited access to CE

Hospital Pharmacy Technician's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Compounding Be Ready to Use Sterile Compounding Technology
Med Safety Help Transition to ENFit for Oral Liquid Meds
COVID-19 Limit Confusion and Other Issues With Paxlovid
Stroke Expect ICH Treatment to Focus on Bleeding and Blood Pressure
Specialty Meds Optimize Use of Specialty Medications
Look-Alike/Sound-Alike Stay Alert for the Latest Med Name Mix-Ups
Education and Training Integrate Learners Into Your Pharmacy
New Drugs Watch for Tirzepatide, a New Injectable Diabetes Med
Antidepressants Some Patients Will Take Antidepressant Combos